Research Analysts Issue Forecasts for BMY FY2028 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Stock analysts at William Blair lifted their FY2028 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued to clients and investors on Tuesday, September 2nd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $5.67 per share for the year, up from their previous forecast of $5.61. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share.

A number of other equities analysts have also issued reports on the company. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Citigroup cut their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, August 1st. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a report on Tuesday, August 5th. Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Finally, Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $56.38.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $46.65 on Thursday. The stock’s 50 day moving average price is $47.07 and its 200 day moving average price is $50.56. The firm has a market capitalization of $94.96 billion, a PE ratio of 18.81, a price-to-earnings-growth ratio of 2.43 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb has a one year low of $42.96 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Institutional Trading of Bristol Myers Squibb

Several institutional investors have recently modified their holdings of BMY. Brighton Jones LLC lifted its holdings in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG purchased a new stake in Bristol Myers Squibb in the 4th quarter worth about $13,094,000. Cary Street Partners Financial LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter worth about $2,301,000. BOKF NA lifted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. BOKF NA now owns 103,029 shares of the biopharmaceutical company’s stock worth $5,752,000 after acquiring an additional 1,464 shares in the last quarter. Finally, Centiva Capital LP lifted its stake in Bristol Myers Squibb by 8.7% in the 4th quarter. Centiva Capital LP now owns 19,671 shares of the biopharmaceutical company’s stock worth $1,113,000 after acquiring an additional 1,580 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. Bristol Myers Squibb’s dividend payout ratio is presently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.